Quipt Home Medical (QIPT) investor relations material

Executive summary

• Revenue for the quarter ended December 31, 2025, increased 32% year-over-year to $80.996 million, driven by acquisitions and organic growth.

• Net loss was $1.053 million, a slight improvement from a net loss of $1.084 million in the prior year period.

• Adjusted EBITDA rose to $17.812 million from $13.997 million year-over-year.

• The company entered into an Arrangement Agreement to be acquired for $3.65 per share, with closing expected in the first half of 2026.

Financial highlights

• Total revenue grew by $19.615 million, with $17.871 million from acquisitions and $1.744 million from organic growth (3%).

• Cost of inventory sold was $22.775 million (28.1% of revenue), slightly improved from 28.9% in the prior year.

• Operating expenses increased 37% to $41.571 million, mainly due to acquisition-related costs and higher payroll/benefits.

• Depreciation and amortization totaled $12.553 million, up from $10.994 million year-over-year.

• Net cash provided by operating activities was $8.941 million, nearly flat year-over-year.

Outlook and guidance

• Priorities for fiscal 2026 include driving organic revenue growth, achieving operational net profit, generating positive cash flow, and expanding Adjusted EBITDA.

• Focus remains on expanding presence in existing and new markets, optimizing structure, and enhancing operational efficiencies.